TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05967507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope
Description: 0.2 L/kg/min FiO2 1.0 low-flow nasal supplemental oxygen with a conventional nasal cannula during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal supplemental oxygen (Fisher & Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope
Description: 2 L/kg/min FiO2 1.0 high-flow nasal supplemental oxygen (Fisher \& Paykel, Auckland, New Zealand) during tracheal intubation with the C-MAC video laryngoscope (Karl Storz, Tuttlingen, Germany) with Miller-blade or Macintosh-blade size No. 0 or No. 1.
Study: NCT05408741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Intervention Group
Description: Participants will complete a 20-minute guided imagery exercise (which includes deep breathing exercises) every day at home using the selected app and/or resource you downloaded at the beginning of this study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Control Group
Description: Participants will continue to receive your current care, but will not receive guided imagery or deep breathing exercises from a social worker.
Study: NCT06499064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Follow-up and treatment of patients in the mHealth arm will be based on a comprehensive solution for the care and monitoring of chronic patients, modelled and tested in chronic HF patients. This is the PIRENe platform, previously described and evaluated in HF patients. It is a digital solution, external to the centre's information systems (external platform). However, it has some special features in its design in terms of remote monitoring, educational tools, among others, expressly conceived and designed for patients with ATTR-CM. This platform allows the provision of multichannel service and monitoring of patients through:~1. Patient monitoring of: Biometric data and symptom report.~2. Generation and management of warning alarms notified to the professionals assigned to each patient in case one of the following situations occurs.~3. Follow-up via videoconference.
Study: NCT05988554

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sachet
Description: Consume 1 sachet daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa extract and collagen products
Description: Consume 1 sachet daily
Study: NCT05680064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue, lip, chin exercise group
Description: In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tongue, lip, chin exercise group
Description: In order to evaluate the effect of chewing gum and tongue, lip and chin exercises on salivary flow rate, xerostomia and dysphagia, both intervention groups will work in a determined time frame daily.
Study: NCT05090215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and resistance training 12 week exercise programme
Description: See arm/group description

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Venous blood sampling
Description: full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood sampling
Description: full blood count, urea \& electrolytes, C-reactive protein, coagulation screen, liver function tests, erythrocyte sedimentation rate.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Muscle Ultrasound
Description: Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Ultrasound
Description: Ultrasound of vastus lateralis to ascertain muscle structure (thickness, pennation angle and fascicle length)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cardiopulmonary exercise testing (CPET)
Description: The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary exercise testing (CPET)
Description: The assessment of anaerobic threshold as a measure of changes in aerobic function between the two groups will be assessed using CPET

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Quality of life questionnaire completion
Description: The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life questionnaire completion
Description: The use of validated questionnaires to assess quality of life parameters; Duke Activity Status Index (DASI), EORTC-QLQ C30 (quality of life for cancer patients) and the International Physical Activity Questionnaire (IPAQ).
Study: NCT05997927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Tablets Placebo
Description: VC005 placebo groups repeat administration for 12 weeks
Study: NCT04239716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: combination of erector spinae plane block and interscalene block for anesthesia in modified radical mastectomy surgeries with axillary lymph node dissection
Study: NCT05428033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: centanafadine capsule
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: centanafadine capsule
Description: capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule
Description: capsule
Study: NCT06108037

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Generative AI for electronic communication and disclosure
Description: We will use a large language model such as GPT 3.5 to automatically generate responses to fictional messages to a physician. We will disclose whether the message was generated using this technology or not. There are 3 clinical scenarios and 6 pairs of human/AI response and human disclosure/AI disclosure/not disclosed that will test patient attitudes toward this technology.
Study: NCT04775589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Exercise for Knee Osteoarthritis
Description: Patients start with a home-based exercise program, supported by an internet-based tool (Step 1). Patients are then assessed for degree of improvement in symptoms, and then can step up sequentially to telephone or video-based physical activity coaching (Step 2) and physical therapy (Step 3) if they do not make clinically relevant improvements in prior steps
Study: NCT04531553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural analgesia
Description: Patients will preoperatively receive thoracic epidural at the level T5 \& T6 with bolus 20 ml of levobupivacaine 0.25% then levobupivacaine 0.1% infused at a rate of 0.1 mL/Kg/hr until chest tube removal ( 5-6 days).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with levobupivacaine and dexmedetomedine
Description: patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% plus 0.5mic/Kg dexmedetomidine on the deep aspect of erector spinae muscle then catheter inserted. 20 ml bolus of levobupivacaine 0.1% with dexmedetomidine 0.5 μg/Kg was injected every 6 hours until chest tube removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB with levobupivacaine
Description: patients will preoperatively receive US guided ESP block on the side to be operates upon, the puncture point of the skin is infiltrated with 2% lidocaine, and once the structures are identified with ultrasound at the level of T5 transverse process, we will inject bolus 20ml of levobupivacaine 0.25% on the deep aspect of erector spinae muscle then catheter inserted.A 20 ml bolus of levobupivacaine 0.1% is injected every 6 hours until chest tube removal.
Study: NCT06231966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy of high-intensity dose rosuvastatin and ezetimibe
Description: Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin monotherapy for treat-to-target
Description: Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)
Study: NCT04642768

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid Ketone Ester
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Commercially available maltodextrin supplement
Study: NCT06051916

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: residual urine
Description: The study includes two group, A and B. Se previously
Study: NCT05902182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ConvaFoam
Description: ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ non-adhesive dressings are designed to provide a moist wound healing environment and removing dead-space between the wound and dressing interface. These dressings are designed to manage excess exudate levels which may further damage the wound bed and surrounding skin. In addition, the dressings are designed to protect fragile skin from moisture, shear, and friction damage. These will be used in line with the patients pressure injury mitigation protocol for a 2 week period, with daily inspections of the skin area.
Study: NCT03947437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEP-F1 + GLA-SE
Description: Leprosy antigen formulated with an adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEP-F1 + GLA-SE
Description: Leprosy antigen formulated with an adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEP-F1 + GLA-SE
Description: Leprosy antigen formulated with an adjuvant.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile normal saline for injection.
Study: NCT05171101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAVEN
Description: The MAVEN education training program will be comprised of a 7-day virtual summer institute and a 7-day second virtual summer institute focused on respect-based leadership, senior scientist career planning, evidence-based mentoring, organizational culture problem solving, interdisciplinary team collaboration and inclusivity, effective science thought leadership, and public engagement. These summer institutes will be comprised of didactics, discussions, and interactive individual and team-based activities. Between the institutes there will be 10 months of mentorship, networking, and conduct of institutional change projects.
Study: NCT04847960

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioGaia Probiotic Lozenges
Description: BioGaia Prodentis lozenges is a food supplement for oral health that contains patented lactic acid bacteria Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) Prodentis (a combination of strains of L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) which helps good microorganisms maintain natural balance in the mouth. This product is safe for daily use and this product can be used during pregnancy and breastfeeding. The ingredients of this product are: bulking agent (isomalt), L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289, fully hydrogenated palm oil, peppermint flavoring, menthol flavoring, peppermint oil and sweetener (sucralose). One candy contains a minimum of 200 million live L. reuteri Prodentis. Net weight per candy is 800 mg. Excessive consumption can have a laxative effect due to the sweetener content in the product. This product has obtained a distribution permit in Indonesia with a BPOM number: SI194510521 with the name Probiotic Prodentis (Pro-D).
Study: NCT03919188

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air temperature control (ATC)
Description: Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin servocontrol (SSC)
Description: Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
Study: NCT04651907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: use disposable sterile steel needles to insert to the acupuncture point

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimal acupuncture
Description: The sham-controlled group will be performed with minimal acupuncture (superficial needling) at non-acupoints.
Study: NCT05162963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixed implant denture
Description: Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.
Study: NCT05080998

Intervention type: DIAGNOSTIC_TEST
Intervention: CxBladder Monitor
Description: CxBladder Monitor (CxbM) is a high sensitivity and negative predictive value (NPV) urinary biomarker test to rule-out subjects at low risk of bladder cancer monitoring for recurrence of disease.
Study: NCT04632433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg every 3 weeks
Study: NCT04580485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB106385
Description: INCB106385 will be administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB106385
Description: INCB106385 will be administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA0012 will be administered IV once every 4 weeks (Q4W)
Study: NCT05162963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fixed implant denture
Description: Patients will receive four or six dental implants, four in the mandible or six in the maxilla, depending on the arch to be treated. After an osseointegration phase of 4 to 6 months, two implant prostheses will be made for each patient, one removable, the other fixed. According to the randomization, during an initial period of 6 months, half of the patients will be using the removable prosthesis, the other half the fixed prosthesis. A 15-day washout will be performed. Then, during a second period of 6 months, the patients will be using the second prosthesis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: removable implant denture
Description: removable implant denture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: removable implant denture
Description: removable implant denture
Study: NCT05330286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution given in fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMI070
Description: Oral solution given in fed state
Study: NCT06205277

Intervention type: PROCEDURE
Intervention: Second TURBt
Description: Second TURBt for pT1 NMIBC as per current EAU Guidelines.
Study: NCT05711966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilator for High-frequency Oscillatory Ventilation (HFOV)
Description: This device will be used to perform an HFOV recruitment maneuver before surfactant administration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Less invasive surfactant administration (LISA)
Description: SurfCath™ tracheal instillation catheter, or a 4- 6 F end-hole catheter, according to local protocols will be used for surfactant administration
Study: NCT06053502

Intervention type: OTHER
Intervention: filtering facepiece respirator
Description: Graded exercise test with filtering facepiece respirator
Study: NCT05410184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses group
Description: Except for the preparation of the patient for the procedure, since the colonoscopy procedure takes approximately 30 minutes, 30-minute 360-degree VR video scenes will be watched using the phone and VR head device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mural curtain group
Description: the mural curtain group; they will be asked to focusing the mural curtain with a nature view during the colonoscopy procedure.
Study: NCT06277427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRG-1801 （CAR-T against BCMA）
Description: Patients with refractory LN and ANCA-associated vasculitis will be treated with PRG-1801
Study: NCT06524843

Intervention type: OTHER
Intervention: Analysis
Description: Analysis and review of imaging and clinical data
Study: NCT05684172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: If patients are randomized and assigned to receive intra-arterial tenecteplase thrombolysis, tenecteplase will be injected according to protocol, proceeding to inject TNK through a distal access catheter or microcatheter located proximal to the residual thrombus (if still present) and distally to the origin of the pontine arteries.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: endovascular thrombectomy alone
Description: Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy alone
Description: Patients will receive randomization if the eTICI score on cerebral angiography is 2b-3 and will stop the procedure if they have been assigned to the control group.
Study: NCT05855811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab should initiated within 6 months after the end of treatment for FPC.
Study: NCT04396418

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Randomization between two groups at site level. One cluster with education and one without.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Randomization between two groups at site level. One cluster with education and one without.